a public good project by the
Synthesis
Company
of California

© 2026

Steven B. Sands | doi.page

0 works0 citations0 h-index

Steven B. Sands

Johnson & Johnson (United States)(US)Janssen (Belgium)(BE)Janssen (United States)(US)

Publications by Year

Research Areas

Nicotinic Acetylcholine Receptors Study, Receptor Mechanisms and Signaling, Ion channel regulation and function, Neuroscience and Neuropharmacology Research, Synthesis and Biological Evaluation

Most-Cited Works

→ Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation(2005)930 cited
→ Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid(2006)533 cited
→ Discovery ofN-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia: Synthesis and Structure−Activity Relationship(2006)189 cited
→ Charybdotoxin blocks voltage-gated K+ channels in human and murine T lymphocytes.(1989)154 cited
→ Barium permeability of neuronal nicotinic receptor alpha 7 expressed in Xenopus oocytes(1993)91 cited
→ Calcium permeability of neuronal nicotinic acetylcholine receptor channels in PC12 cells(1991)89 cited

→ Discovery of 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models(2009)

74 cited

→ 3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation(2005)73 cited

→ In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (−)-cytisine(2005)67 cited

→ Neuronal nicotinic acetylcholine receptor currents in phaeochromocytoma (PC12) cells: dual mechanisms of rectification.(1992)65 cited